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Reply to the Editor:
We thank Dr Beghetti and col-
leagues for their thoughtful comments
regarding the hemodynamic evalua-
tion and further management of our re-
cent case of atrial septal defect (ASD).1
The management of patients with a de-
gree of pulmonary vascular disease
prior to shunt closure has been a matter
of debate. In addition, recent studies
demonstrating the efficacy of oral
vasodilators in pulmonary vascular
disease associated with congenital
systemic-to-pulmonary shunts2,3 have
fueled an uncertainty of vasodilator
pretreatments prior to shunt closure.
Despite optimized medical treat-
ment with diuretics, antibiotics, and
oral anticoagulant over 4 months since
the first medical contact, our patient
was severely dyspneic, with elevated
atrial pressures, a pro–brain natriuretic
peptide serum level of above 4000 pg/
mL, and a dramatically limited 6-min-
ute walking distance (6-MWD) of 150
m. In fact, based on the hemodynamic
assessment alone, the patient was ad-
mitted to the surgical ward for ASD
closure. However, surgeons refused
the operation based on the patient’s
overall clinical profile and frailty. A
10-month treatment with bosentan on
top of supportive treatment with di-
uretics and anticoagulation effectively
decreased shunt flow and lowered
pulmonary vascular resistance by 140
dynes $ s1 $ cm5 and markedly de-
creased atrial pressures, biomarkers,
and 6-MWD in the presence of
a mild arterial desaturation.
We do agree with the discussants
that taking into account left atrial pres-
sures, pulmonary arteriolar resistance
was about 3 Woods. In addition, the
pulmonary-to-systemic resistance ra-
tio under oxygen and nitric oxide
was<0.33 (in the patient, this ratio
was 0.11), a threshold pediatric cardi-
ologists have labeled as a criterion
conveying a good prognosis after clo-
sure of the shunt.4 Still, data in adult
patients with congenital heart disease
are lacking, and the criteria of a com-
plete hemodynamic responder status
in adults were not fulfilled in this
case.5 Because hemodynamic testing
is a routine procedure in adult pulmo-
nary vascular centers, we do rely on
these data in the absence of firm evi-
dence indicating their uselessness in
adults with congenital heart disease.
Moreover, children are usually exam-
ined under general sedation/anesthe-
sia. For these and other reasons, it is
evident that the hemodynamic re-
sponse pattern in children is different
from that in adults6 and that hemody-
namic criteria in children may not ap-
ply to elderly adults. Furthermore,
later assessments after surgery in the
patient under discussion illustrated
a degree of persistent pulmonary vas-
cular disease with a pulmonary arterio-
lar resistance of 530 dynes $ s1 $ cm5,
despite active treatment with bosen-
tan.1
The main value of this report is to
provoke discussion, because due to its
single case nature, surgery in the ab-
sence of bosentan cannot be repeated.
We submit that our invasive proce-
dure was based on an integrative
clinical and hemodynamic approach
and guided by numbers, rather than
the reverse. Controlled data to guide
a ‘‘targeted treatment-and-repair’’
strategy in adult patients with congen-
ital heart disease are needed.
Konrad Hoetzenecker, MDa
Hendrik J. Ankersmit, MDa
Irene M. Lang, MDb
Departments of aCardiothoracic
Surgery and
bCardiology Medical University of
Vienna, Austria
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MISMATCH
To the Editor:
I read with interest the article by
Moon and colleagues1 and thank the
authors for their contribution to the
continued debate on the issue of pros-
thesis–patient mismatch (PPM).
PPM is an important topic in current
cardiac surgery, and there are several
discrepancies and contrasting publica-
tions about the effect of PPM on
postoperative outcome.2,3 Some of
these controversies are discussed in
the accompanying counterpoint article
by Dr Feindel.4 In their work Moon
and colleagues1 provide important in-
sight into the management of aortic
valve replacement (AVR) with bio-
prostheses in patients older than 70009
PROSTHESIS–PATIENT
MISMATCH DOES NOTAFFECT
SURVIVAL AND QUALITY OF
LIFE IN THE ELDERLY HAVING
BILEAFLET PROSTHESES
IMPLANT
To the Editor:
We read with interest the article by
Moon and colleagues evaluating the
impact of prosthesis–patient mismatch
(PPM) on the long-term outcomes for
elderly patients having aortic valve
replacement (AVR).1 The study evi-
denced the lack of influence on sur-
vival by PPM after implantation of
biologic prostheses in elderly people.
We would be interested to learn
from the authors whether they evalu-
ated the impact of PPM on incidence
of bioprosthesis degeneration at fol-
low-up.
We agree with authors’ consider-
ation, discussed in the Comment sec-
tion, of the inopportunity of aortic
root enlargement in this subset of
patients, and we also support the iso-
lated AVR for aortic stenosis.
We recently have published a series
on the topic of PPM and reported com-
parable conclusions.2,3 However, we
would like to share with the authors
our different policy regarding the
choice of mechanical prostheses, and
we would like to receive their consid-
eration about this.
In our view, the increased life
expectancy has increased the risk of
reoperation for structural degeneration
of a bioprosthesis during long-term
follow-up. Life expectancy in septua-
genarians can be 14 to 15 years, and
the durability of a bioprosthesis could
be inferior despite the engineering im-
provements. To reduce the probability
of reoperation in the eighth or ninth
decade of life, we apply precise selec-
tive criteria to the choice of biologic or
mechanical prosthesis.
As reported in our previous stud-
ies,4,5 the choice of prosthetic implants
for old patients was fundamentally
guided by the consideration of pa-
tient’s biologic age and associated
with the foreseeable life expectancy.
We chose mechanical devices for
elderly patients who reasonably had
a life expectancy of more than 10 to
12 years. Moreover, patients already
receiving long-term anticoagulation
for chronic atrial fibrillation were
offered a mechanical prosthesis. Bio-
logic prostheses were preferred for
those patients with contraindication
to oral anticoagulation or those in
whom general senescence status or
associated multiple noncardiac comor-
bidities, or both, suggested a life
expectancy of less than 10 years. The
incidence of anticoagulation-related
complications is very low, with a free-
dom from hemorrhagic event of
96.9%  0.013% at 10 years.
Our institution includes an outpa-
tient clinic that monitors anticoagula-
tion therapy in a number of elderly
Letters to the Editoryears. In their study of 1399 patients
undergoing AVR, PPM had a negative
effect on late survival for patients
younger than 70 years but did not in-
fluence late survival in patients older
than 70 years.
Mohty and associates2 similarly
found that AVR, with either a biopros-
thesis or a mechanical valve, does not
increase late mortality in patients older
than 70 years. As Moon and col-
leagues1 outline in their discussion of
the study’s limitations, they do not ad-
dress the effects on late functional state
or left ventricular mass regression, and
moreover, they do not mention quality
of life (QOL).
In my opinion, it is very important to
consider a good QOL as a goal for most
operations. Especially in the elderly
population, it is important to maintain
or improve QOL in addition to pro-
longing life. Koch and coworkers5
found that factors other than prosthe-
sis/patient size ratio influence func-
tional QOL after AVR. Yamaguchi
and colleagues6 suggested that im-
provement in QOL can be expected af-
ter heart valve replacement in patients
older than 70 years. However, their
study population was different from
that of Moon and colleagues1 and in-
cluded mechanical and bioprosthetic
valves placed in multiple positions; ad-
ditionally, we do not know whether the
PPM occurred in the AVRs in the se-
ries of Yamaguchi and colleagues.6
PPM affects left ventricular remod-
eling, surgical outcome, and late mor-
tality, and therefore should be
considered a diseased state.2 It is im-
portant to know whether PPM in el-
derly patients influences recovery
after AVR.
If Moon and colleagues1 have data
about the QOL of their 1399 patients,
the information derived from these
data could help us understand how
PPM affects QOL and would be highly
relevant in the care of elderly patients
undergoing AVR.
Stefano Salizzoni, MD
Division of Cardiothoracic Surgery–The JournHeart, Lung and Esophageal Surgery
Institute
University of Pittsburgh Medical
Center
Pittsburgh, Pa
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